Health
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J., September 23, 2025--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/a2853fea4657d4cd3d3d9efa3599b3f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8sX0vICnayIQWS8gV4szIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a2853fea4657d4cd3d3d9efa3599b3f0","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lGMRBT53HgNLlppm_0aFUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a2853fea4657d4cd3d3d9efa3599b3f0","width":1024,"height":512}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., September 23, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD™), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM) demonstrated a statistically significant improvement in minimal residual disease (MRD) negativity rates, compared with the control arm, in a planned interim analysis of the MRD endpoint. In accordance with the trial design and based on the recommendation from the Data Monitoring Committee, the trial will continue without changes to evaluate the other dual-primary endpoint of progression-free survival (PFS), and the key secondary endpoint of overall survival and safety. The safety profile of iberdomide in combination with daratumumab and dexamethasone in this study is generally consistent with previous studies.","length":967,"tagName":"p"},{"type":"text","content":""This result builds on our significant experience in both targeted protein degradation and developing new treatment options for patients living with multiple myeloma," said Anne Kerber, Senior Vice President, Head of Development, Hematology, Oncology and Cell Therapy. "Iberdomide represents the first of a novel class of medicines, called CELMoDs, which has the potential to create a new foundation for multiple myeloma treatment that may be combined with other therapies."","length":494,"tagName":"p"},{"type":"text","content":"The company plans to discuss these results with healt...